BackgroundCheck.run
Search For

Mark L Cushman, 745389 Pearl St, Rancho Cucamonga, CA 91701

Known as:
Mark Lawrence Cushman Mark C Cushman Mark Cushuam
Related to:
David Cushman 43 Cynthia A Cushman 72 Candace L Cushman 72 David R Cushman 37

Mark Cushman Phones & Addresses

5389 Pearl St, Rch Cucamonga, CA 91701    909-9008312   

11718 White Mountain Ct, Rancho Cucamonga, CA 91737   

Alta Loma, CA   

2639 County Road 500, Bayfield, CO 81122   

Moreno Valley, CA   

Crofton, MD   

Littleton, CO   

5389 Pearl St, Rancho Cucamonga, CA 91701   

Work

Company: Immanuel's church Address: 16819 New Hampshire Avenue, Silver Spring, MD 20905 Phones: 240-9883806 Position: Partner Industries: Religious Organizations
Get Report
Control this profile

Mentions for Mark L Cushman

Resumes & CV records

Resumes

Mark Cushman Photo 28

President At Bio-Pure Products, Inc.

Position:
President at Bio-Pure Priducts, Inc.
Location:
Gardnerville, Nevada
Industry:
Biotechnology
Work:
Bio-Pure Priducts, Inc.
President
Mark Cushman Photo 29

Mark Cushman

Location:
United States

Publications & IP owners

Us Patents

B-Homoestra-1,3,5(10)-Trienes As Modulators Of Tubulin Polymerization

US Patent:
6696436, Feb 24, 2004
Filed:
Aug 16, 2002
Appl. No.:
10/111664
Inventors:
Ernest Hamel - Bethesda MD
Mark S. Cushman - West Lafayette IN
Assignee:
The United States of America as represented by the Department of Health and Human Services - Washington DC
International Classification:
A61K 3155
US Classification:
51421204, 514529, 514546, 540519, 560139, 568376, 568719
Abstract:
The invention provides B-ring expanded estra-1,3,5(10)-triene compounds of general formula (1) which modulate the polymerization of tubulin and/or the depolymerization of microtubules. The compounds have anti-angiogenic and anti-tumor activity. The invention also provides methods of preparing the compounds, and methods of using the compounds for the treatment of cancer or other mammalian diseases characterized by undesirable angiogenesis. The compounds of the invention are also expected to have utility as research tools.

1,2-Dihydroellipticines With Activity Against Cns Specific Cancer

US Patent:
5441941, Aug 15, 1995
Filed:
Dec 21, 1993
Appl. No.:
8/171234
Inventors:
Rudiger D. Haugwitz - Bethesda MD
Mark Cushman - West Lafayette IN
Jurjus Jurayj - West Lafayette IN
Assignee:
The United States of America as represented by the Secretary of DHHS - Washington DC
Purdue Research Foundation - Lafayette IN
International Classification:
A61K 31435
A61K 31535
C07D47104
US Classification:
514 43
Abstract:
Certain new 1,2-dihydroellipticine compounds having activity against CNS specific cancer cell lines because of their ease of passage across the blood-brain barrier are disclosed along with formulations and methods for treating CNS cancers employing these compounds.

Possible Relatives

Cynthia Cushman  David H Cushman  Deborah A Cushman  Daniel B Cushman  Aaron R Cushman  Denis K Cushman  Darlene O Cushman  Mark W Johnson  Mark E Stamps  Mark Stancil 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.